Edgar A Samaniego1,2, Vladimir Kalousek3, German Abdo2, Santiago Ortega-Gutierrez1. 1. Division of Interventional Neuroradiology/Endovascular Neurosurgery, Department of Neurology, Neurosurgery and Radiology, University of Iowa, Iowa City, USA. 2. Departamento de Neuroradiologia Intervencionista, Hospital Eugenio Espejo, Quito, Ecuador. 3. Department of Radiology, Clinical Hospital Center "Sestre Milosrdnice", Zagreb, Croatia.
Abstract
OBJECTIVE: To describe our early experience in treating cerebral arteriovenous malformations (AVMs) with the new Precipitating Hydrophobic Injectable Liquid (PHIL) embolic material. MATERIALS AND METHODS: Between June and August 2015 five patients with cerebral AVMs were treated at two tertiary university hospitals. PHIL was used as complementary treatment to Onyx liquid embolic material or as the sole endovascular treatment. RESULTS: Five patients (average age 39 years (range 19-73)) with ruptured plexiform AVMs were treated. The group included one patient with Spetzler-Martin grade II AVMs, three grade III, and one grade IV. One grade II and two grade III AVMs were cured. A total of nine pedicles were embolized with an average of two pedicles per session. There were no procedural complications. One patient had a seizure after embolization but a brain CT scan showed no hemorrhage. CONCLUSIONS: PHIL is a new embolic agent that can be used for the treatment of cerebral AVMs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: To describe our early experience in treating cerebral arteriovenous malformations (AVMs) with the new Precipitating Hydrophobic Injectable Liquid (PHIL) embolic material. MATERIALS AND METHODS: Between June and August 2015 five patients with cerebral AVMs were treated at two tertiary university hospitals. PHIL was used as complementary treatment to Onyx liquid embolic material or as the sole endovascular treatment. RESULTS: Five patients (average age 39 years (range 19-73)) with ruptured plexiform AVMs were treated. The group included one patient with Spetzler-Martin grade II AVMs, three grade III, and one grade IV. One grade II and two grade III AVMs were cured. A total of nine pedicles were embolized with an average of two pedicles per session. There were no procedural complications. One patient had a seizure after embolization but a brain CT scan showed no hemorrhage. CONCLUSIONS: PHIL is a new embolic agent that can be used for the treatment of cerebral AVMs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
Arteriovenous Malformation; Embolic; Liquid Embolic Material
Authors: Jingjie Hu; Hassan Albadawi; Brian W Chong; Amy R Deipolyi; Rahul A Sheth; Ali Khademhosseini; Rahmi Oklu Journal: Adv Mater Date: 2019-06-06 Impact factor: 30.849
Authors: Edgar A Samaniego; Colin P Derdeyn; Minako Hayakawa; David Hasan; Santiago Ortega-Gutierrez Journal: Interv Neuroradiol Date: 2018-07-04 Impact factor: 1.610
Authors: Dominik F Vollherbst; Ruth Otto; Thuy Do; Hans U Kauczor; Martin Bendszus; Christof M Sommer; Markus A Möhlenbruch Journal: Interv Neuroradiol Date: 2018-07-04 Impact factor: 1.610
Authors: D F Vollherbst; C M Sommer; C Ulfert; J Pfaff; M Bendszus; M A Möhlenbruch Journal: AJNR Am J Neuroradiol Date: 2017-05-18 Impact factor: 3.825